{"id":"NCT01047553","sponsor":"AstraZeneca","briefTitle":"Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients","officialTitle":"An Open Phase III, Multi-centre 52-week, Parallel-group Study Evaluating the Safety and Efficacy of Formoterol 18 μg Daily Dose Compared With Standard COPD Treatment, in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12","primaryCompletion":"2011-01","completion":"2011-07","firstPosted":"2010-01-13","resultsPosted":"2013-01-04","lastUpdate":"2013-01-04"},"enrollment":251,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Formoterol (OT)","otherNames":["Oxis Turbuhaler®"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"This study is a multicentre, open, randomised, parallel-group study with formoterol 9 μg one inhalation b.i.d, or standard COPD therapy. Standard (reference) COPD treatment arm should be the group to refer to when safety results of formoterol arm will be evaluated. 240 patients with moderate-to-severe COPD will be randomised (120 patients in the formoterol-arm and 120 patients on standard COPD therapy).","primaryOutcome":{"measure":"Clinical Laboratory Test: Haematology -Erythrocytes","timeFrame":"Baseline and week 52","effectByArm":[{"arm":"Arm 1 - Formoterol","deltaMin":-6.25,"sd":23.8},{"arm":"Arm 2 - Standard Treatment","deltaMin":-5.2,"sd":27.5}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":27,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":125},"commonTop":["NASOPHARYNGITIS","Back Pain","Chronic Obstructive Pulmonary Disease","Bronchitis","Pneumonia"]}}